Media coverage about C.R. Bard (NYSE:BCR) has trended somewhat positive on Thursday, Accern Sentiment reports. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. C.R. Bard earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 46.5754335212719 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media stories that may have effected Accern’s scoring:

A number of analysts have recently issued reports on the company. Jefferies Group LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Cowen and Company reaffirmed a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a research report on Friday, November 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th. Finally, Barclays PLC lifted their target price on C.R. Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research report on Monday, November 6th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $303.50.

C.R. Bard (NYSE:BCR) traded down $1.48 during trading hours on Thursday, reaching $335.18. The company had a trading volume of 551,800 shares, compared to its average volume of 660,727. The firm has a market capitalization of $24,539.94, a P/E ratio of 29.07, a price-to-earnings-growth ratio of 2.57 and a beta of 0.53. C.R. Bard has a fifty-two week low of $206.26 and a fifty-two week high of $336.98. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.57.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, topping the Zacks’ consensus estimate of $2.96 by $0.06. The business had revenue of $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period last year, the firm earned $2.64 earnings per share. analysts expect that C.R. Bard will post 11.89 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be paid a $0.26 dividend. The ex-dividend date is Thursday, December 7th. This represents a $1.04 dividend on an annualized basis and a yield of 0.31%. C.R. Bard’s dividend payout ratio (DPR) is 13.70%.

In related news, Vice Chairman John H. Weiland sold 33,435 shares of C.R. Bard stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $333.31, for a total value of $11,144,219.85. Following the completion of the transaction, the insider now directly owns 76,331 shares in the company, valued at $25,441,885.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Frank Lupisella, Jr. sold 7,035 shares of C.R. Bard stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $334.70, for a total value of $2,354,614.50. Following the completion of the transaction, the vice president now owns 13,824 shares of the company’s stock, valued at $4,626,892.80. The disclosure for this sale can be found here. Insiders sold 191,593 shares of company stock valued at $62,655,513 over the last quarter. Insiders own 0.80% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “C.R. Bard (BCR) Receives Daily News Impact Rating of 0.19” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/c-r-bard-bcr-receives-daily-news-impact-rating-of-0-19/1722429.html.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.